Role of C-type natriuretic peptide signalling in maintaining cartilage and bone function  by Peake, N.J. et al.
Osteoarthritis and Cartilage 22 (2014) 1800e1807ReviewRole of C-type natriuretic peptide signalling in maintaining cartilage
and bone function
N.J. Peake y, A.J. Hobbs z, B. Pingguan-Murphy x, D.M. Salter k, F. Berenbaum ¶,
T.T. Chowdhury y *
y Institute of Bioengineering, School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London E1 4NS, UK
z William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square,
London EC1M 6BQ, UK
x Department of Biomedical Engineering, Faculty of Engineering, University of Malaya, 50603 Kuala Lumpur, Malaysia
k Centre for Genomics and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crew Road,
Edinburgh EH4 2XU, UK
¶ Sorbonne Universites, Universite Pierre et Marie Curie Paris 06, INSERM UMRS 938, Assistance Publique-Hopitaux de Paris,
Department of Rheumatology and DHU i2B, Ho^pital Saint-Antoine, Paris, Francea r t i c l e i n f o
Article history:
Received 19 March 2014
Accepted 22 July 2014
Keywords:
Osteoarthritis
Inﬂammation
C-type natriuretic peptide
Natriuretic peptide receptor
Cartilage homeostasis* Address correspondence and reprint requests to
Engineering and Materials Science, Queen Mary Un
Road, London E1 4NS, UK. Tel: 44-(0)207-8827560.
E-mail address: t.t.chowdhury@qmul.ac.uk (T.T. Ch
http://dx.doi.org/10.1016/j.joca.2014.07.018
1063-4584/© 2014 Osteoarthritis Research Society Ins u m m a r y
C-type natriuretic peptide (CNP) has been demonstrated in human and mouse models to play critical
roles in cartilage homeostasis and endochondral bone formation. Indeed, targeted inactivation of the
genes encoding CNP results in severe dwarﬁsm and skeletal defects with a reduction in growth plate
chondrocytes. Conversely, cartilage-speciﬁc overexpression of CNP was observed to rescue the pheno-
type of CNP deﬁcient mice and signiﬁcantly enhanced bone growth caused by growth plate expansion.
In vitro studies reported that exogenous CNP inﬂuenced chondrocyte differentiation, proliferation and
matrix synthesis with the response dependent on CNP concentration. The chondroprotective effects
were shown to be mediated by natriuretic peptide receptor (Npr)2 and enhanced synthesis of cyclic
guanosine-30,50-monophosphate (cGMP) production. Recent studies also showed certain homeostatic
effects of CNP are mediated by the clearance inactivation receptor, Npr3, highlighting several mecha-
nisms in maintaining tissue homeostasis. However, the CNP signalling systems are complex and inﬂu-
enced by multiple factors that will lead to altered signalling and tissue dysfunction. This review will
discuss the differential role of CNP signalling in regulating cartilage and bone homeostasis and how the
pathways are inﬂuenced by age, inﬂammation or sex. Evidence indicates that enhanced CNP signalling
may prevent growth retardation and protect cartilage in patients with inﬂammatory joint disease.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular joint function is known to be dependent on the ho-
meostasis of multiple tissue types. Bones develop and grow into
adulthood through the expansion and differentiation of chon-
drocytes at the cartilaginous growth plate through a process known
as endochondral ossiﬁcation. Initially, mesenchymal precursor cells
condense in the centre and undergo differentiation into large
chondrocytes that proliferate in a longitudinal manner character-
istic of the growth plate1. The cells eventually stop proliferating and: T.T. Chowdhury, School of
iversity of London, Mile End
owdhury).
ternational. Published by Elsevier Lundergo terminal differentiation into hypertrophic chondrocytes
that ultimately promote the vascularisation, mineralisation and
recruitment of osteoclasts and osteoblasts which replace the
calciﬁed cartilage matrix with bone2. The process of hyaline carti-
lage formation that covers the articular surface leads to the depo-
sition of extracellular matrix components and provides the
structural properties that facilitate normal joint biomechanics. In
turn, biomechanical signals promote beneﬁcial anabolic activities
in chondrocytes facilitating normal remodelling mechanisms and
tissue homeostasis. However, in age-related diseases of the joint,
the integrity of the extracellular matrix is lost, leading to disruption
of cell function, abnormal signalling and reduced load-bearing
function. Indeed, weakening of bone structure leads to osteopo-
rosis (OP) and loss of cartilage integrity results in osteoarthritis
(OA).td. All rights reserved.
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ulates cardiac and vascular function3, promoting homeostatic ef-
fects involving hyperpolarisation and cell proliferation in a manner
dependent on the cell type and concentration4e7. CNP is distinct
from other natriuretic peptides, with emerging evidence for its
ability to regulate cartilage and bone homeostasis. The develop-
ment of transgenic mouse models that target the CNP signalling
system has helped to deﬁne the importance of this peptide in
cartilage and bone8e18. In clinical studies, dwarf patients with
acromesomelic dysplasia, type Maroteaux (AMDM) were found to
have autosomal recessive Npr2 functional deletions leading to
stunted skeletal growth but no deﬁciency in CNP levels19. In addi-
tion, Npr2 functional halploinsufﬁciency that occurs in family
members of AMDM patients were reported to have short stature20.
This is in contrast to CNP overproductionwhich has been associated
with bone overgrowth and skeletal deformations21,22. Human
genome-wide association studies have demonstrated a link be-
tween CNP and height variation and circulating CNP levels predict
height, with a close correlation to linear growth in healthy chil-
dren23,24. Accordingly, plasma CNP levels are at a maximum at
puberty, and gradually decline into adulthood25. The importance of
the natriuretic peptide signalling pathway in the musculoskeletal
system is therefore evident in both animals and humans. Conse-
quently, there has been great interest in the biological effects of
CNP and their inﬂuence on tissue homeostasis. In this review, we
will discuss the role of CNP signalling in bone and cartilage tissues
and how homeostatic functions may be inﬂuenced by age,
inﬂammation or sex and lead to the onset and development of joint
disease.
CNP/Npr2 signalling is critical for bone homeostasis
The skeletal defects observed in CNP and natriuretic peptide
receptor (Npr) knockout mouse models are summarised in Table I
and highlight the major phenotypes of CNP signalling in bone.
CNP binds to two cell-surface receptors, Npr2 and Npr3, which are
expressed in osteoblasts as well as chondrocytes. The effects of CNP
are mediated via Npr2, which possesses guanylyl cyclase (GC) ac-
tivity and leads to synthesis of cyclic guanosine-30,50-mono-
phosphate (cGMP). Deletion of Npr2 mimics the skeletal defects
associated with loss of CNP and defective Npr2 is responsible for
dwarﬁsm in patients with AMDM19 and subsequently conﬁrmed inTable I
In vivo evidence indicating a role for CNP/Npr signalling in the skeleton
Genotype Phenotype
Nppc/ - 10% loss of body weight at birth
- 30e40% reduction of growth
- No signiﬁcant differences in organ/body weight
- Stunted tail/bones
- 50% birth rate
- Reduced skull size and shortened jaws
- Size and mortality rescued by systemic over-expression
Npr3/ - Increased circulating ANP and ANP half-life
- Normal birth rate, but 50% mortality before weening
- Enhanced urine production and water intake
- Hunched backs, dome-shaped skull, elongated tails and
- Increased body length
- Decreased weight
FGFR3/ - Achondroplasia rescued by targeted cartilage-speciﬁc C
Prkg/ - Dwarﬁsm not rescued by targeted CNP over-expression
Lbab/Lbab - Long bone abnormality caused by a spontaneous mutat
- Rescued by cartilage-speciﬁc expression of CNP
cn/cn - Spontaneous missense mutation in Npr2 leading to dwa
- Notable lack of cGMP production in response to CNP
CNPcol2a1TG and K/BxN TCR - Inﬂammatory arthritis model displaying growth delay,
- Symptoms rescued by cartilage-speciﬁc expression of Canimal models with loss of function mutation of the Npr2 gene in
the cn/cn mouse17. In addition, carrier parents of children with
AMDM were noted to be shorter than average20,26. Recent studies
have also shown loss of functionmutation in Npr2 leading to severe
dwarﬁsm, skeletal dysplasia and infertility in AMDM pa-
tients8,17,27,28. In animal studies, targeted disruption of genes
encoding CNP showed severe dwarﬁsm and early death as a result
of impaired endochondral ossiﬁcation characterised by a defective
growth plate9,12e14. The inhibition in growth plate chondrocytes
caused a 10% reduction in length in contrast to intramembranous
bones which were of normal size9. In contrast, overstimulation of
Npr2/GC causes skeletal overgrowth disorders11,15,29,30. Npr3 does
not possess GC functionality, but acts as a clearance inactivation
receptor and subjects natriuretic peptides to lysosomal degrada-
tion, thereby regulating Npr2 signalling29. Indeed, deletion of Npr3
in mice supports this model with signiﬁcant overgrowth observed,
most notably leading to distinctive arching of the back29. Further-
more, cartilage speciﬁc over-expression of CNP in growth plate
chondrocytes rescued the phenotype of Nppc-deﬁcient mice11. For
example, no signiﬁcant differences were observed in the naso-anal
length between tg/Nppc/ mice and Nppcþ/þ mice9, clearly indi-
cating that CNP is critical for bone formation.
The impact of the CNP signalling pathway in vitro appears to be
dependent on the model system and celltype (Table II). Previous
studies showed that CNP stimulated cell differentiation by
increasing gene expression for alkaline phosphatase and oseto-
calcin and mineralisation of nodules in osteoblastic MC3T3-E1 cells
and osteoblast-like cells from newborn rat calvaria31e33. These
observations are consistent with the effects of CNP in primary
cultures of fetal rat calvaria where the peptide induced osteoblast
differentiation and showed synergy with factors such as osteogenic
protein-1 (OP-1)34. The enhanced bone growth in mouse tibia
cultured with CNP increased cGMP signalling through Npr2, and
inﬂuenced the MEK (MAP/ERK kinase) Erk 1/2 kinase and p38
mitogen activated protein kinase (MAPK) cascades35. Recent
studies reported differential effects of CNP on cell proliferationwith
the response dependent on the cell type36,37. In an earlier study,
CNPwas shown to activate osteoclast bone resorption activities in a
cGMP-dependent manner in osteoclast containing mouse bone
marrow cultures38. It is possible that the bone marrow cultures
treated with CNP forced the undifferentiated stem cells in these
cultures towards chondrogenesis via endochondral bone growthReference
of CNP
[9e11]
bones
[29]
NP expression and by systemic CNP over-expression [62]
, therefore linking CNP to cGKII signalling [13]
ion in CNP leading to reduced (30e100 fold) binding to Npr2 [14e16]
rﬁsm, short limbs and tail due to defective endochondral ossiﬁcation [17]
diminished chondrocyte proliferation and ECM synthesis
NP
[18]
Table II
Summary of in vitro cell functional studies examining the effect of CNP in cartilage and bone
Species Cell type Model Functional effect of CNP Reference
Mouse Human Osteoblastic cell line (Mouse
MC3T3-E1 and human CRL-11372)
Monolayer - Dose-dependent increases in cGMP
- CNP levels augmented with TGFb1
- Differential effects on cell proliferation and alkaline phosphatase activity with
enhanced DNA levels in CRL-11372 cells.
- Mineralisation (calcium, biglycan) associated with differentiation in MC3T3-E1 cells
- Enhanced type I collagen and osteocalcin
[32,33,37]
Human Osteosarcoma cell line (MG-63,
Saos-2 and HOS)
Monolayer - Differential effects on cell proliferation with a reduction for MG-63 cells
- Growth dependent on cell type
[36]
Rat Primary osteoblast Monolayer - Increased OP-1 induced alkaline phosphatase activity
- Enhanced Smad5 phosphorylation
- Differentiation characterised by matrix deposition and reduced cell proliferation.
[31,34]
Rat Chondrosarcoma cells Monolayer - CNP antagonised FGF-2-induced growth arrest by inhibition of Erk 1/2 pathway
- Abolished MEK and Raf-1 but not Ras
- Restored ECM and inhibits several MMPs
[49]
Murine Osteoclast containing mouse bone
marrow
Monolayer - Increased cGMP production and osteoclast bone resorptive activity
- No effect on osteoclast formation.
[38]
Murine ATDC5 chondrogenic cell line Monolayer - Differentiation characterised by enhanced ECM deposition and type X collagen
synthesis
- Reduced cell proliferation
- Inhibition of FGF mediated Erk 1/2
[42,48]
Bovine Chondrocytes Pellet - Increased cell proliferation and matrix synthesis
- Anabolic effects dependent on CNP concentration
[39]
Human Chondrocytes 3D/bioreactor - Increased cell proliferation and ECM via Npr2/cGMP/PKGII.
- CNP and dynamic compression counteracts inﬂammatory effects induced by IL-1b
- Shows beneﬁcial/reparative effects by CNP and dynamic compression
[40,44]
Chicken MSCs Micromass/
pellet
- Differentiation characterised by enhanced ECM deposition
- GAG and N-cadherin production
[41]
Murine Embryonic mesenchymal cells Micromass - ECM deposition, GAGs, Link protein, chondroitin-6-sulfotransferase 3 expression
- N-cadherin production
- Cellular condensations
[43]
Human Trabecular bone derived MSCs Pellet - Chondrogenic differentiation characterised by enhanced GAG synthesis in a dose-
dependent manner with TGFb1 and CNP
- Reduced cell proliferation.
[46]
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bone resorption activity of osteoclasts for remodelling. The in vitro
observations highlight the importance of the CNP signalling
pathway in promoting bone formation through regulation of
osteoblast activity.
CNP signalling in cartilage tissue homeostasis
Similar to observations with osteoblasts, the signalling effects of
CNP in chondrocytes are primarily mediated via Npr2/GC/cGMP
(Fig. 1). However, chondrocytes express both Npr2 and Npr3 and
the peptide has been shown to bind to Npr3 with high afﬁnity39,40.
The effects of exogenous CNP in monolayer, pellet or 3D in vitro
models on chondrocyte differentiation, proliferation and ECM
synthesis are presented in Table II. CNP treatment of chicken
mesenchymal stem cells, chondrogenic cell lines or bovine chon-
drocytes cultured in pellet culture leads to increased type II
collagen and proteoglycan synthesis (aggrecan), reduced cell pro-
liferation, increased chondrocyte condensations and N-cadherin
expression, indicating a switch from proliferative to differentiated
and hypertrophic chondrocytes, mediated by Npr239,41,42. The
enhanced matrix synthesis but not cell proliferation in response to
CNP occurs via increased activity of the enzymes involved in
chondroitin sulphate synthesis and GAG production43. In a human
chondrocyte/3D agarose model, CNP enhanced the synthesis of
collagens and proteoglycans, and inﬂuenced cell proliferation in a
concentration-dependent manner, implying that this peptide has
potential protective effects in human cartilage44. Furthermore, we
showed that CNP is critical in maintaining cartilage function and
promotes anabolic effects when applied in combination with a
compressive regimen designed to mimic physiological exercise44.
We identiﬁed the mechanism that promotes the beneﬁcialrelationship between CNP and dynamic compression and showed
that Npr2 mediates chondroprotective effects in human cartilage
via cGMP production and cyclic GMP-dependent protein kinase II
(PKGII) activation (Fig. 2). We also reported that treatment with
agents that speciﬁcally activate Npr3 (cANF423) were found to
enhance the beneﬁcial effects of CNP such that the protective and
reparative response on matrix production was augmented with
mechanical loading (Fig. 2)40. The Npr3 agonist may either block
Npr3 clearance function or synergise with signalling via Npr2 or
both. In concert, our ﬁndings imply that Nprs are key molecules in
maintaining normal cartilage function and mediate the beneﬁcial
response to mechanical loading.
Transforming growth factor b (TGFb) is known to be critical for
the differentiation of chondrocytes. Indeed, the presence of TGFb
upregulates CNP/Npr2 levels and subsequent cGMP production in
bone marrow derived mesenchymal stem cells45,46. The combina-
tion of CNP and TGFb appears to be additive with effects dependent
on peptide concentration46,47. As well as enhanced signalling
through Npr2, there appears to be a parallel decrease in Npr3
expression with differentiation45. It is interesting that CNP/Npr2
signalling inhibits the downstream effects of ﬁbroblast growth
factor-2 (FGF-2), mediated through inhibition of Erk1/2 phos-
phorylation and theMEK/ERK cascade at the level of RAF-1, through
its activation of PKGII and leads to stunted growth in a murine
model of achondroplasia48,49. The cytoprotective effects of CNP
were shown to bemediated in part via the Gi/ocoupled Npr3 leading
to Erk1/2 activation and regulation of endothelial and vascular
smooth muscle cell proliferation50. The MEK pathway may there-
fore crossover with the Npr3/Gi/o-linked Erk1/2 signalling events
previously identiﬁed in maintaining homeostatic function in
vascular cells50. However, the pathways will be dependent on the
cell type and concentration of CNP. In chondrocytes, low CNP
Fig. 1. Homeostatic and inﬂammatory effects of CNP signalling in the knee joint. CNP is an important regulator of joint homeostasis and endochondral bone growth. During
homeostasis (indicated by green arrows), CNP activates Npr2/cGMP and PKGII signalling which upregulates matrix components (aggrecan, collagen type II, chondroitin synthases) in
articular cartilage and bone growth/mineralisation (alkaline phosphatase) leading to normal tissue remodelling and biomechanics. In addition, Npr2 signalling inhibits activation of
the MEK/ERK MAPK pathway regulating joint homeostasis. In cases of joint disease (indicated by red arrows), inﬂammatory synovial proliferation and vascularisation leads to a
reduction in Npr2 expression and the protective effects are compromised. In this situation, Npr3 is the dominant receptor and protects cells by reduced clearance function to
promote signalling via CNP/Npr2 or stimulates anabolic effects via Erk1/2 in an attempt to maintain homeostatic function. However, high CNP concentrations will lead to
dysfunctional signalling via the MEK/ERK pathway which is catabolic. The inﬂammatory environment leads to production of cytokines, NO, MMPs which breakdown cartilage and
interfere with normal tissue biomechanics.
Fig. 2. Signalling pathways activated by CNP in cartilage. CNP primarily activates Npr2 leading to an increase in cGMP and PKGII levels. This response was inhibited by the
selective Npr2 antagonist, P19. It has been reported that Npr3 acts as a clearance/inactivation receptor for CNP thereby modulating signalling via Npr2. However, the Gi/o binding
domain in Npr3 activates Erk1/2 and supports cartilage homeostasis by mediating extracellular matrix (ECM) synthesis when cells are treated with the Npr3 agonist, cANF423.
Loading designed to mimic physiological exercise stimulate Npr expression and CNP levels, which leads to upregulation of ECM. In contrast, IL-1b stimulates catabolic activities via
inducible nitric oxide synthase (iNOS) and NO levels. The enhanced cGMP production in response to IL-1bwas reduced with the soluble guanylyl cyclase (sGC) antagonist, ODQ. The
IL-1b-induced catabolic response was prevented by CNP and mechanical signals leading to restoration of ECM.
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promote differentiation and matrix synthesis without affecting cell
proliferation, mirroring the concentration-dependent effects of
CNP in vascular cells43,50. Npr3may therefore have differential roles
depending on local CNP levels. At low CNP concentrations, Npr3 is
the dominant receptor and slows clearance function to promote
actions via Npr2 or activates Erk1/2 to maintain homeostatic
function (Fig. 1). At high CNP concentrations, Npr2 is highly active
and inhibits the activation of the MEK/ERK pathway49. This model
brings a fresh perspective on the importance in the balance be-
tween these two receptors.
Effect of inﬂammation on CNP/Npr signalling
It is well established that pro-inﬂammatory cytokines such as
interleukin-1b (IL-1b) and tumour necrosis factor-a (TNFa) disturb
normal activities of chondrocytes by increasing production of nitric
oxide (NO), prostaglandin E2 (PGE2) and matrix metalloproteinases
(MMPs). The accumulation of inﬂammatory factors enhances
catabolic driven pathways that contribute to eventual loss of matrix
components and biomechanical damage. The link between CNP and
inﬂammation in chondrocytes is unclear and there is no evidence to
date on the effect of the peptide in synovial cells. However, in
vascular cells, CNP was enhanced by lipopolysaccharide (LPS), IL-1b
or TNFa and has an anti-inﬂammatory role in vascular disease51,52.
In the only study which examined the effect of IL-1b on natriuretic
peptide receptors in chondrocytes treated with CNP, the cytokine
was reported to increase CNP levels and Npr3 expression, thereby
augmenting potential beneﬁcial effects mediated by Npr signal-
ling40. In general, inﬂammation was previously shown to upregu-
late CNP levels but in children, peptide levels were found to be
reduced53, presenting potential complications on growth relevant
to young patients with Juvenile Idiopathic Arthritis (JIA). Since
there is strong evidence for a role of endogenous CNP signalling in
normal cartilage development, the potential therapeutic role for
exogenous CNP in the treatment of skeletal growth disorders
should be investigated further. For example, there is good evidence
that disruption of the CNP/Npr system has implications in inﬂam-
matory disease. In a murine model of inﬂammatory arthritis,
transgenic mice engineered to overexpress chondrocyte-speciﬁc
CNP showed increased growth and reduced arthritis severity18.
Furthermore, the animals were less sensitive to inﬂammatory cy-
tokines and were protected against cartilage damage. This study
has clear implications for JIA and highlight that enhanced CNP
signalling may prevent growth retardation and protect cartilage in
patients with inﬂammatory joint disease18. Our work has also
shown that CNP acts in an anti-inﬂammatory manner, dampening
the effects of IL-1b on NO and PGE2 levels and mediating the
reparative response on matrix synthesis in chondrocytes isolated
from individuals with OA40,44. This response may explain the po-
tential beneﬁcial effects of CNP on reducing the symptoms of
arthritis and highlights the need for the examination of CNP in OA
animal models.
CNP in ageing and onset of disease
Ageing is a major risk factor for joint disease and has been linked
to CNP dysfunction, including abnormal cartilage/bone function
and pro-inﬂammatory signalling (Fig. 1). There is some evidence
that CNP levels decrease with age and may primarily affect sig-
nalling via Npr3. For example, in chondrocytes and osteoblasts
derived from older tissues, there is a shift in the levels of Npr
expression with age, such that Npr3 is the dominant receptor40,54.
This has clear implications on CNP signalling, although currently it
is not known whether Npr3 favours CNP clearance and reducesNpr2/cGMP signalling or the pathway is switched to Erk 1/2 kinase
and MEK 1 activation which is involved in chronic inﬂammatory
joint disease (Fig. 1). Further analysis of the age-linked changes are
therefore needed to explain why cartilage is more prone to injury
and why tissues become more susceptible to damage with ageing.
There is some evidence that CNP expression and activity is linked to
sex. In children with short stature due to growth hormone deﬁ-
ciency, testosterone was observed to increase plasma levels of
CNP25. In adults, NT-proCNP levels were generally higher in men in
the 5th decade compared to adolescent values with similar but less
marked changes in women, indicating a possible relationship be-
tween CNP and sex55. However, it is difﬁcult to deﬁne exactly
whether CNP levels are affected by sex since there is no direct ev-
idence of the peptide on sex hormones in animal or human studies.
The level of CNP may reﬂect controlled systemic quantities from
vascular tissues with differences due to demographics (e.g., BMI,
height), rather than sex hormones. It is well known that CNP levels
are always at a baseline in adults. However, the differences in CNP
levels after menopause in women or in elderly men are not known.
We could speculate that the older age groups might be more prone
to develop joint disease due to deﬁciencies in CNP signalling and
diminished cartilage protection. Studies to examine the age/sex
effects on CNP should therefore be investigated since the differ-
ences in the Npr2/3 signalling mechanism may underlie sex dif-
ferences and predisposition to joint disease. Such understanding
might allow the subsequent development of targeted treatments
and therapy options for injury prone and aged individuals with
dysfunctions of CNP signalling in older cartilage.
CNP based potential therapeutics
Pharmacological targeting of CNP or interventions designed to
affect Nprs and mimic the actions of CNP may represent a valuable
avenue to enhance repair mechanisms and stabilise joint tissue
homeostasis. A major decision will be whether to deliver therapies
locally or systemically since the latter approach will inﬂuence the
disease process throughout the body rather than in one affected
joint and may be of more beneﬁt to individuals with multiple
involved joints. However, it will be necessary to consider the
adverse effects on other cell types that express Nprs and potential
off-target effects in joints and other tissues in which CNP signalling
is highly active after puberty. Nonetheless, CNP based therapies are
advancing towards clinical application for several conditions. For
example, treatment with a 39 amino acid CNP analog (BMN 111) in
Fgfr3 gain of function mouse model of achondroplasia, leads to
signiﬁcant recovery of bone growth mediated by Npr2/cGMP sig-
nalling56. The peptide has an extended plasma half-life due to its
resistance to neutral endopeptidase digestion and shows proof of
concept that BMN 111 might beneﬁt individuals with skeletal
dysplasias. Furthermore, the use of CNP agents that activate GC-
B and mimic the actions of CNP/Npr2 signalling was proposed for
the treatment of achondroplasia57. However, this study did not
identify a chemical agent or its pharmacodynamic activity and
therefore CNP as a therapeutic approach is still under question.
Furthermore, current treatment options for joint disorders are
suboptimal for most patients due to poor targeting of therapeutics
to the pathological site to maximise disease-modifying activities,
efﬁcacy and reduce side effects. Since CNP regulates cardiac and
vascular function, complications to both systems will be a concern.
The anti-inﬂammatory effects observed in response to CNP may
also lead to increased risk of infection, and since the peptide acts to
promote proliferation and growth, a risk of neoplastic changes may
also be present. Targeted, localised delivery methods could help to
address some of these concerns especially in patients with mono-
articular disease, but efﬁcacy studies that meet optimal safety
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articular use. In addition, unmodiﬁed agents delivered in this
manner are likely to be efﬁciently removed58. As such novel de-
livery methods may be required to improve efﬁcacy of treatment
through maintaining both an optimal intrarticular concentration
and a retention proﬁle that prevents spill over into systemic cir-
culation. Previous biomaterial strategies for delivering therapies
in vivo include the use of liposomes, hydrogels or nanoparticles to
maximise the disease-modifying effects of drugs in the OA
joint59e61. This method was shown to reduce drug clearance and
allow higher dosing than systemic administration of metho-
trexate62. Intra-articular targeting with microcapsules containing
CNP based agents might also improve delivery to joint tissue and
could expose cells to higher drug concentrations with formulations
to enhance retention and thus maintain sustained delivery. How-
ever, the injections will improve only individual joints and this
strategy may serve as a better option for cartilage repair secondary
tomechanical trauma or injury for tissue regeneration. Accordingly,
a beneﬁt-risk assessment dependent on OA phenotype should be
performed in order to choose the optimal approach (systemic or
local) for the administration of therapeutics targeting CNP.
Conclusions
There is extensive evidence to support a role for CNP in main-
taining homeostatic function in cartilage and bone. However, the
biology of CNP signalling in joint tissues is complex and will be
inﬂuenced by several factors leading to dysfunction and disease.
The differences in themechanism of Npr signalling affect the ability
of the peptide to function normally. This will have widespread
impact due to the role of CNP in maintaining joint homeostasis and
may crosstalk with other mechanisms linking angiogenesis and
osteogenesis with function in vascular systems63,64. The differential
effects of Nprs in response to signals that inﬂuence their expression
will therefore determine the CNP signalling system and their effects
on tissue function. Therapeutic application of CNP or interventions
targeted to natriuretic peptide receptors to inﬂuence the actions of
CNP, should therefore be considered to speed up repair mecha-
nisms and stabilise tissue homeostasis.
Author contribution
All authors contributed to conception and design, manuscript
preparation, read and approved the ﬁnal manuscript.
Conﬂict of interests
None declared.
Acknowledgements
The work was supported by the AO Research Fund of the AO
Foundation (S-09-83C), Arthritis Research UK (19646) and UMHigh
Impact Research Grant (UM.C/HIR/MOHE/ENG/44) from the Min-
istry of Higher Education Malaysia.
References
1. Kronenberg HM. Developmental regulation of the growth
plate. Nature 2003;423:332e6.
2. Karsenty G, Kronenberg HM, Settembre C. Genetic control of
bone formation. Annu Rev Cell Dev Biol 2009;25:629e48.
3. Clavell AL, Stingo AJ, Wei CM, Heublein DM, Burnett JC. C-type
natriuretic peptide: a selective cardiovascular peptide. Am J
Physiol 1993;264:R290e5.4. Khambata RS, Panayiotou CM, Hobbs AJ. Release of C-type
natriuretic peptide accounts for the biological activity of
endothelial-derived hyperpolarizing factor. Proc Natl Acad Sci
USA 2003;100:1426e31.
5. Cahill PA, Hassid A. Clearance receptor-binding atrial natri-
uretic peptides inhibit mitogenesis and proliferation of rat
aortic smooth muscle cells. Biochem Biophys Res Commun
1991;179:1606e13.
6. Ahluwalia A, Hobbs AJ. Endothelium-derived C-type natri-
uretic peptide: more than just a hyperpolarizing factor. Trends
Pharmacol Sci 2005;26:162e7.
7. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic
peptides: their structures, receptors, physiologic functions and
therapeutic applications. Handb Exp Pharmacol 2009;191:
341e66.
8. Fujii T, Komatsu Y, Yasoda A, Kondo E, Yoshioka T, Nambu T,
et al. Circulating C-type natriuretic peptide (CNP) rescues
chondrodysplastic CNP knockout mice from their impaired
skeletal growth and early death. Endocrinology 2010;151:
4381e8.
9. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T,
et al. Dwarﬁsm and early death in mice lacking C-type natri-
uretic peptide. Proc Natl Acad Sci USA 2001;98:4016e21.
10. Kake T, Kitamura H, Adachi Y, Yoshioka T, Watanabe T,
Matsushita H, et al. Chronically elevated plasma C-type natri-
uretic peptide level stimulates skeletal growth in transgenic
mice. Am J Physiol Endocrinol Metab 2009;297:E1339e48.
11. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A,
Miura M, et al. Overexpression of CNP in chondrocytes rescues
achondroplasia through a MAPK-dependent pathway. Nat
Med 2004;10:80e6.
12. Komatsu Y, Chusho H, Tamura N, Yasoda A, Miyazawa T,
Suda M, et al. Signiﬁcance of C-type natriuretic peptide (CNP)
in endochondral ossiﬁcation: analysis of CNP knockout mice.
J Bone Miner Metab 2002;20:331e6.
13. Miyazawa T, Ogawa Y, Chusho H, Yasoda A, Tamura N,
Komatsu Y, et al. Cyclic GMP-dependent protein kinase II plays
a critical role in C-type natriuretic peptide-mediated endo-
chondral ossiﬁcation. Endocrinology 2002;143:3604e10.
14. Tsuji T, Kondo E, Yasoda A, Inamoto M, Kiyosu C, Nakao K, et al.
Hypomorphic mutation in mouse Nppc gene causes retarded
bone growth due to impaired endochondral ossiﬁcation. Bio-
chem Biophys Res Commun 2008;376:186e90.
15. Kondo E, Yasoda A, Tsuji T, Fujii T, Miura M, Kanamoto N, et al.
Skeletal analysis of the long bone abnormality (lbab/lbab)
mouse, a novel chondrodysplastic C-type natriuretic peptide
mutant. Calcif Tissue Int 2012;90:307e18.
16. Yoder AR, Kruse AC, Earhart CA, Ohlendorf DH, Potter LR.
Reduced ability of C-type natriuretic peptide (CNP) to activate
natriuretic peptide receptor B (NPR-B) causes dwarﬁsm in
lbab/ mice. Peptides 2008;29:1575e81.
17. Tsuji T, Kunieda T. A loss-of-function mutation in natriuretic
peptide receptor 2 (Npr2) gene is responsible for dispropor-
tionate dwarﬁsm in cn/cn mouse. J Biol Chem 2005;280:
14288e92.
18. Bukulmez H, Khan F, Bartels CF, Murakami S, Ortiz-Lopez A,
Sattar A, et al. Protective effects of C-type natriuretic peptide
on linear growth and articular cartilage integrity in an in-
ﬂammatory arthritis mouse model. Arthritis Rheum 2014;66:
78e89.
19. Bartels CF, Bükülmez H, Padayatti P, Rhee DK, van Rav-
enswaaij-Arts C, Pauli RM, et al. Mutations in the trans-
membrane natriuretic peptide receptor NPR-B impair skeletal
growth and cause acromesomelic dysplasia, type Maroteaux.
Am J Hum Genet 2004;75:27e34.
N.J. Peake et al. / Osteoarthritis and Cartilage 22 (2014) 1800e1807180620. Olney RC, Bükülmez H, Bartels CF, Prickett TC, Espiner EA,
Potter LR, et al. Heterozygous mutations in natriuretic peptide
receptor-B (NPR2) are associated with short stature. J Clin
Endocrinol Metab 2006;91:1229e32.
21. Tassano E, Buttgereit J, Bader M, Lerone M, Divizia MT,
Bocciardi R, et al. Genotype-phenotype correlation of 2q37
deletions including gene associated with skeletal malforma-
tions. PLoS One 2013;8:e66048.
22. Bocciardi R, Giorda R, Buttgereit J, Gimelli S, Divizia MT, Beri S,
et al. Overexpression of the C-type natriuretic peptide (CNP) is
associated with overgrowth and bone anomalies in an indi-
vidual with balanced t(2;7) translocation. Hum Mutat
2007;28:724e31.
23. Estrada K, Krawczak M, Schreiber S, van Duijn K, Stolk L, van
Meurs JB, et al. A genome-wide association study of north-
western Europeans involves the C-type natriuretic peptide
signaling pathway in the etiology of human height variation.
Hum Mol Genet 2009;18:3516e24.
24. Olney RC, Permuy JW, Prickett TC, Han JC, Espiner EA. Amino-
terminal propeptide of C-type natriuretic peptide (NTproCNP)
predicts height velocity in healthy children. Clin Endocrinol
(Oxf) 2012;77:416e22.
25. Olney RC, Prickett TC, Yandle TG, Espiner EA, Han JC, Mauras N.
Amino-terminal propeptide of C-type natriuretic peptide and
linear growth in children: effects of puberty, testosterone, and
growth hormone. J Clin Endocrinol Metab 2007;92:4294e8.
26. Borrelli P, Fasanelli S, Marini R. Acromesomelic dwarﬁsm in a
child with an interesting family history. Pediatr Radiol
1983;13:165e8.
27. Khan S, Ali RH, Abbasi S, Nawaz M, Muhammad N, Ahmad W.
Novel mutations in natriuretic peptide receptor-2 gene un-
derlie acromesomelic dysplasia, type Maroteaux. BMC Med
Genet 2012;13:44.
28. Geister KA, Brinkmeier ML, Hsieh M, Faust SM, Karolyi IJ,
Perosky JE, et al. A novel loss-of-function mutation in Npr2
clariﬁes primary role in female reproduction and reveals a
potential therapy for acromesomelic dysplasia, Maroteaux
type. Hum Mol Genet 2013;22:345e57.
29. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S,
Yamauchi M, et al. The natriuretic peptide clearance receptor
locally modulates the physiological effects of the natriuretic
peptide system. Proc Natl Acad Sci USA 1999;96:7403e8.
30. Miura K, Namba N, Fujiwara M, Ohata Y, Ishida H, Kitaoka T,
et al. An overgrowth disorder associated with excessive pro-
duction of cGMP due to a gain-of-function mutation of the
natriuretic peptide receptor 2 gene. PLoS One 2012;7:e42180.
31. Hagiwara H, Inoue A, Yamaguchi A, Yokose S, Furuya M,
Tanaka S, et al. cGMP produced in response to ANP and CNP
regulates proliferation and differentiation of osteoblastic cells.
Am J Physiol 1996;270(5 Pt 1):C1311e8.
32. Inoue A, Hayakawa T, Otsuka E, Kamiya A, Suzuki Y, Hirose S,
et al. Correlation between induction of expression of biglycan
and mineralization by C-type natriuretic peptide in osteo-
blastic cells. J Biochem 1999;125:103e8.
33. Suda M, Tanaka K, Fukushima M, Natsui K, Yasoda A,
Komatsu Y, et al. C-type natriuretic peptide as an autocrine/
paracrine regulator of osteoblast. Evidence for possible pres-
ence of bone natriuretic peptide system. Biochem Biophys Res
Commun 1996;223:1e6.
34. Yeh LC, Zavala MC, Lee JC. C-type natriuretic peptide en-
hances osteogenic protein-1-induced osteoblastic cell dif-
ferentiation via Smad5 phosphorylation. J Cell Biochem
2006;97:494e500.
35. Agoston H, Khan S, James CG, Gillespie JR, Serra R, Stanton LA,
et al. C-type natriuretic peptide regulates endochondral bonegrowth through p38 MAP kinase-dependent and independent
pathways. BMC Dev Biol 2007;7:18.
36. Shaikh N, Russo L, Papaleo E, Giannoni P, De Gioia L, Nicotra F,
et al. C-type natriuretic peptide: structural studies, fragment
synthesis, and preliminary biological evaluation in human
osteosarcoma cell lines. Biopolymers 2010;94:213e9.
37. Lenz A, Bennett M, Skelton WPt, Vesely DL. Vessel dilator and
C-type natriuretic peptide enhance the proliferation of human
osteoblasts. Pediatr Res 2010;68:405e8.
38. Holliday LS, Dean AD, Greenwald JE, Glucks SL. C-type natri-
uretic peptide increases bone resorption in 1,25-
dihydroxyvitamin D3-stimulated mouse bone marrow cul-
tures. J Biol Chem 1995;270:18983e9.
39. Waldman SD, Usmani Y, Tse MY, Pang SC. Differential effects of
natriuretic peptide stimulation on tissue-engineered cartilage.
Tissue Eng Part A 2008;14:441e8.
40. Peake N, Su N, Ramachandran M, Achan P, Salter DM, Bader DL,
et al. Natriuretic peptide receptors regulate cytoprotective ef-
fects in a human ex vivo 3D/bioreactor model. Arthritis Res
Ther 2013;15:R76.
41. Alan T, Tufan AC. C-type natriuretic peptide regulation of limb
mesenchymal chondrogenesis is accompanied by altered N-
cadherin and collagen type X-related functions. J Cell Biochem
2008;105:227e35.
42. Suda M, Tanaka K, Yasoda A, Komatsu Y, Chusho H, Miura M,
et al. C-type natriuretic peptide/guanylate cyclase B system in
ATDC5 cells, a chondrogenic cell line. J Bone Miner Metab
2002;20:136e41.
43. Woods A, Khan S, Beier F. C-type natriuretic peptide regulates
cellular condensation and glycosaminoglycan synthesis during
chondrogenesis. Endocrinology 2007;148(10):5030e41.
44. Ramachandran M, Achan P, Salter DM, Bader DL,
Chowdhury TT. Biomechanical signals and the C-type natri-
uretic peptide counteract catabolic activities induced by IL-
1beta in chondrocyte/agarose constructs. Arthritis Res Ther
2011;13:R145.
45. Fujishige K, Kotera J, Yanaka N, Akatsuka H, Omori K. Alter-
ation of cGMP metabolism during chondrogenic differentia-
tion of chondroprogenitor-like EC cells, ATDC5. Biochim
Biophys Acta 1999;1452:219e27.
46. Tezcan B, Serter S, Kiter E, Tufan AC. Dose dependent effect of
C-type natriuretic peptide signaling in glycosaminoglycan
synthesis during TGFb1induced chondrogenic differentiation
of mesenchymal stem cells. J Mol Histol 2010;41:247e58.
47. Kocamaz E, Gok D, Cetinkaya A, Tufan AC. Implication of C-
type natriuretic peptide-3 signaling in glycosaminoglycan
synthesis and chondrocyte hypertrophy during TGFb1 induced
chondrogenic differentiation of chicken bone marrow-derived
mesenchymal stem cells. J Mol Histol 2012;43:497e508.
48. Ozasa A, Komatsu Y, Yasoda A, Miura M, Sakuma Y,
Nakatsuru Y, et al. Complementary antagonistic actions be-
tween C-type natriuretic peptide and the MAPK pathway
through FGFR-3 in ATDC5 cells. Bone 2005;36:1056e64.
49. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H,
et al. Interaction of ﬁbroblast growth factor and C-natriuretic
peptide signaling in regulation of chondrocyte proliferation
and extracellular matrix homeostasis. J Cell Sci 2005;118:
5089e100.
50. Khambata RS, Panayiotou CM, Hobbs AJ. Natriuretic peptide
receptor-3 underpins the disparate regulation of endothelial
and vascular smooth muscle cell proliferation by C-type
natriuretic peptide. Br J Pharmacol 2011;164:584e97.
51. Suga S, Itoh H, Komatsu Y, Ogawa Y, Hama N, Yoshimasa T,
et al. Cytokine-induced C-type natriuretic peptide (CNP)
secretion from vascular endothelial cellseevidence for CNP as
N.J. Peake et al. / Osteoarthritis and Cartilage 22 (2014) 1800e1807 1807a novel autocrine/paracrine regulator from endothelial cells.
Endocrinology 1993;133:3038e41.
52. Qian JY, Haruno A, Asada Y, Nishida T, Saito Y, Matsuda T, et al.
Local expression of C-type natriuretic peptide suppresses
inﬂammation, eliminates shear stress-induced thrombosis,
and prevents neointima formation through enhanced nitric
oxide production in rabbit injured carotid arteries. Circ Res
2002;91:1063e9.
53. Prickett TC, Hector-Taylor J, Olney RC, Darlow BA, Espiner EA.
Acute inﬂammation in young children inhibits C-type natri-
uretic peptide. Pediatr Res 2013;74:191e5.
54. Kaneki H, Kurokawa M, Ide H. The receptor attributable to C-
type natriuretic peptide-induced differentiation of osteoblasts
is switched from type B- to type C-natriuretic peptide receptor
with aging. J Cell Biochem 2008;103:753e64.
55. Prickett TC, Olney RC, Cameron VA, Ellis MJ, Richards AM,
Espiner EA. Impact of age, phenotype and cardio-renal func-
tion on plasma C-type and B-type natriuretic peptide forms in
an adult population. Clin Endocrinol (Oxf) 2013;78:783e9.
56. Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E,
Oppeneer T, et al. Evaluation of the therapeutic potential of a
CNP analog in a Fgfr3 mouse model recapitulating achondro-
plasia. Am J Hum Genet 2012;91:1108e14.
57. Yasoda A, Kitamura H, Fujii T, Kondo E, Murao N, Miura M,
et al. Systemic administration of C-type natriuretic peptide as anovel therapeutic strategy for skeletal dysplasias. Endocri-
nology 2009;150:3138e44.
58. Evans CH, Kraus VB, Setton LA. Progress in intra-articular
therapy. Nat Rev Rheumatol 2014;10:11e22.
59. Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in
osteoarthritis. Adv Drug Deliv Rev 2006;58:226e42.
60. Reeff J, Gaignaux A, Goole J, De Vriese C, Amighi K. New
sustained-release intraarticular gel formulations based on
monolein for local treatment of arthritic diseases. Drug Dev
Ind Pharm 2013;39:1731e41.
61. Kang ML, Lm G. Drug delivery systems for intra-articular
treatment of osteoarthritis. Exp Opin Drug Deliv 2014;11:
269e82.
62. Butoescu N, Jordan O, Doelker E. Intra-articular drug delivery
systems for the treatment of rheumatic diseases: a review of
the factors inﬂuencing their performance. Eur J Pharm Bio-
pharm 2009;73:205e18.
63. Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angio-
genesis and osteogenesis by a speciﬁc vessel subtype in bone.
Nature 2014;507:323e8.
64. Kusumbe AP, Ramasamy SK, Wang L, Adams RH. Endothelial
notch activity promotes angiogenesis and osteogenesis in
bone. Nature 2014;507:376e80.
